India and the Patent Wars: Pharmaceuticals in the New Intellectual Property Regime - Murphy Halliburton
- Format: Broché Voir le descriptif
Vous en avez un à vendre ?
Vendez-le-vôtre35,62 €
Produit Neuf
Ou 8,91 € /mois
- Livraison à 0,01 €
- Livré entre le 18 et le 30 mai
Expédition rapide et soignée depuis l`Angleterre - Délai de livraison: entre 10 et 20 jours ouvrés.
- Payez directement sur Rakuten (CB, PayPal, 4xCB...)
- Récupérez le produit directement chez le vendeur
- Rakuten vous rembourse en cas de problème
Gratuit et sans engagement
Félicitations !
Nous sommes heureux de vous compter parmi nos membres du Club Rakuten !
TROUVER UN MAGASIN
Retour
Avis sur India And The Patent Wars: Pharmaceuticals In The New Intellectual Property Regime de Murphy Halliburton Format... - Livres
0 avis sur India And The Patent Wars: Pharmaceuticals In The New Intellectual Property Regime de Murphy Halliburton Format... - Livres
Les avis publiés font l'objet d'un contrôle automatisé de Rakuten.
Présentation India And The Patent Wars: Pharmaceuticals In The New Intellectual Property Regime de Murphy Halliburton Format...
- Livres
Résumé :
India and the Patent Wars contributes to an international debate over the costs of medicine and restrictions on access under stringent patent laws showing how activists and drug companies in low-income countries seize agency and exert influence over these processes. Murphy Halliburton contributes to analyses of globalization within the fields of anthropology, sociology, law, and public health by drawing on interviews and ethnographic work with pharmaceutical producers in India and the United States.
India has been at the center of emerging controversies around patent rights related to pharmaceutical production and local medical knowledge. Halliburton shows that Big Pharma is not all-powerful, and that local activists and practitioners of ayurveda, India's largest indigenous medical system, have been able to undermine the aspirations of multinational companies and the WTO. Halliburton traces how key drug prices have gone down, not up, in low-income countries under the new patent regime through partnerships between US- and India-based companies, but warns us to be aware of access to essential medicines in low- and middle-income countries going forward.
Détails de conformité du produit
Personne responsable dans l'UE